Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D337
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
D337 is an investigational pharmaceutical agent that is being developed as a component of various combination therapies for the treatment of conditions such as hypertension, dyslipidemia, and hyperlipidemia. It has also been studied in combination for Type 2 Diabetes Mellitus. Clinical trials have evaluated its pharmacokinetic properties, safety, and efficacy when co-administered with other compounds like CKD-828, D326, D097, D013, D086, D012, and CKD-331, often as part of formulations like CKD-348, CKD-391, and CKD-386. The specific mechanism of action for D337 alone is not detailed in the provided context, but its role in these combination therapies suggests it contributes to the management of cardiovascular and metabolic disorders.
Beyond the preview
Go deeper on D337.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D337.